A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
• Life expectancy >=3 months.
• Female patients of childbearing age should agree to use contraceptive measures duringthe study period and for at least 6 months after study is stopped; male patientsshould agree to use contraception during the study period and for at least 6 monthsafter study is stopped.
• Understood and signed an informed consent form.

Exclusion Criteria:

• Diagnosed and/or treated additional malignancy within 5 years before the first dose.
• With factors affecting oral medication.
• Received major surgical treatment, open biopsy or obvious traumatic injury within 4weeks before the first dose.
• A history of psychotropic drug abuse or have a mental disorder.
• Any severe and/or uncontrolled diseas.
• Has received Chinese patent medicines with anti-tumor indications within 2 weeksbefore the first dose.
• Has participated in other clinical studies within 4 weeks before the first dose.
• According to the judgement of the investigators, there are other factors that subjectsare not suitable for the study.